Abstract: Disclosed is a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.

Abstract: Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.

Abstract: The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.

Abstract: The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.

Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Abstract: Disclosed is a pharmaceutical composition including, in a pharmaceutically acceptable carrier: at least one anti-CD303 antibody; and at least one anti-AMHRII antibody. Also disclosed is the combination of the two aforementioned antibodies a) and b) to form a combination product to be used simultaneously, separately or spread out over a period of time, for the prevention or treatment of urogenital cancers. Also disclosed is a method for preventing or treating an urogenital cancer in a subject in need thereof, such method including administering to the subject products containing: at least one anti-CD303 antibody; and at least one anti-AMHRII antibody.

Abstract: A composition includes monoclonal antibodies directed against a circulating proinflammatory cytokine, the antibodies having a high affinity for the Fc?RIIIa receptor (CD16), in particular the fucose level of all of the antibodies of the composition being less than 60%, and preferably less than 50%, and in particular, the galactosylation level of all of the antibodies of the composition being at least 60%, for the use thereof in the context of the prevention or treatment of the early phases of inflammation. A composition including monoclonal antibodies directed against a circulating bacterial toxin, having an improved affinity for the Fc?RIIIa receptor (CD16) with respect to antibodies directed against the bacterial toxin, produced in the CHO cell line, for the use thereof in the context of the prevention or treatment of the early phases of a bacterial infection linked to the release of the toxin is also described.

Abstract: Disclosed is a pharmaceutical composition including, in a pharmaceutically acceptable carrier: a) at least one anti-CD303 antibody; and b) at least one anti-HER2 antibody. Also disclosed is the combination of the two aforementioned antibodies a) and b) to form combination products to be used simultaneously, separately or spread out over a period of time, for the prevention or treatment of HER2-positive cancer.

Abstract: The invention relates to a cell line expressing the gamma chain of the Fc?RI receptor and human CD303 antigen, characterized in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc?RI receptor and human CD303 antigen, and different uses of the cell line of the invention.

Abstract: The present invention relates to the use of antibody Fc fragments in the treatment of autoimmune and/or inflammatory diseases, said Fc fragments being isolated recombinant Fc fragments having a modified affinity for at least one of the Fc receptors (FcR), particularly an increased affinity to FcRn.

Abstract: The present invention relates to a chimeric protein comprising at least one human amyloid P component and at least one fragment of an Fc region of a human antibody, the human amyloid P component and the fragment of an Fc region with which it is associated being bound to each other by means of a hinge region.

Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP).

Abstract: The invention relates to chimeric or humanised anti-CD303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (BPDCN) or inflammatory diseases, in particular autoimmune diseases, involving plasmacytoid dendritic cells.

Abstract: The invention relates to a cell line expressing the gamma chain of the Fc?RI receptor and human CD303 antigen, characterised in that said cell line is transfected in a stable manner by an expression vector comprising a nucleic acid molecule coding for human CD303 antigen and having strong expression of human CD303 on the surface thereof, e.g. at least 10000 molecules of human CD303 per cell, as well as a vector or vector kit that can be used to co-express the gamma chain of the Fc?RI receptor and human CD303 antigen, and different uses of the cell line of the invention.

Abstract: Disclosed is to a polypeptide including a mutated Fc region and having functional activity, mediated by the Fc region, that is modified compared with that of a parent polypeptide. The Fc region includes at least one combination of 2 mutations, the combination being selected from among one mutation selected from among a first set of mutations, and at least one mutation selected from among a second set of mutations, and provided that mutation (i) does not take place on the same amino acid as mutation (ii). Also disclosed are use of the polypeptide, compositions including the same, and methods for preparing the polypeptide.

Abstract: The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.

Abstract: The present invention relates to a monoclonal antibody method directed against CD20 antigen including administration of an anti CD20 antibody wherein each of the light chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 28, and each of the heavy chains thereof has the murine-human chimeric amino acid sequence SEQ ID NO: 20.

Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure.

Abstract: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADCC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunization in Rh negative persons, in particular for hemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP).